Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	1^st May 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,743,481 (2.073%)		-
(2) Derivatives (other than options)	-		-
(3) Options and agreements to purchase/sell	276,800 (0.121%)		1,298,000 (0.567%)
Total	5,020,281 (2.194%)		1,298,000 (0.567%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Purchase	30	111.46
Purchase	106	111.45
Purchase	303	111.82
Purchase	20	111.64
Purchase	100	111.50
Purchase	60	111.73
Purchase	106	111.70
Purchase	545	111.74
Purchase	250	111.72
Purchase	143	111.76
Purchase	32	111.49
Purchase	8	111.57
Purchase	183	111.66
Purchase	17	111.71
Purchase	100	111.80
Purchase	2,231	111.77
Purchase	360	111.85
Purchase	271	111.79
Purchase	75	111.93
Purchase	571	111.84
Purchase	389	111.88
Purchase	325	111.91
Purchase	80	111.98
Sale	30	112.00
Purchase	100	111.52
Purchase	331	111.53
Purchase	278	111.94
Purchase	311	111.69
Purchase	100	111.48
Purchase	200	111.46
Purchase	105	111.47
Purchase	2	111.45
Purchase	90	111.82
Purchase	2	111.42
Purchase	198	111.62
Purchase	200	111.73
Purchase	900	111.72
Purchase	110	111.76
Purchase	162	111.96
Purchase	99	111.67
Purchase	200	111.81
Purchase	38	111.83
Purchase	200	111.77
Purchase	491	111.85
Purchase	100	111.84
Sale	9,085	111.95
Purchase	884	111.65
Purchase	300	111.89
Sale	5	111.47
Sale	24	111.74
Sale	50	111.76
Sale	109	111.80
Sale	2,285	111.77
Sale	4	111.79
Purchase	241	111.95
Purchase	4,795	111.48
Purchase	920	111.46
Purchase	1,700	111.47
Purchase	1	111.38
Purchase	1	111.37
Purchase	97	111.39
Purchase	1,339	111.45
Purchase	2	111.36
Purchase	3,307	111.44
Purchase	3,519	111.82
Purchase	130	111.42
Purchase	663	111.64
Purchase	144	111.50
Sale	2,000	111.50
Purchase	1,799	111.90
Purchase	3,981	111.75
Sale	609	111.75
Purchase	110	111.73
Purchase	203	111.70
Purchase	142	111.74
Sale	2,253	111.74
Purchase	855	111.72
Purchase	1,473	111.76
Sale	193	111.76
Purchase	132	111.49
Purchase	200	111.43
Purchase	442	111.68
Purchase	19	111.57
Purchase	123	111.66
Purchase	846	111.71
Purchase	726	111.92
Purchase	426	111.67
Purchase	100	111.99
Purchase	893	111.81
Purchase	2,414	111.83
Sale	233	111.83
Purchase	3,906	111.80
Sale	1,449	111.80
Purchase	418	111.77
Sale	677	111.77
Purchase	425	111.55
Purchase	703	111.85
Sale	1,861	111.85
Purchase	360	111.60
Purchase	786	111.61
Purchase	1,226	111.79
Sale	1,652	111.79
Purchase	2,067	111.93
Purchase	300	111.87
Purchase	579	111.84
Purchase	2,924	111.88
Purchase	300	111.91
Purchase	100	111.98
Sale	10	111.98
Purchase	638	111.95
Sale	412	111.95
Purchase	886	111.86
Purchase	2,228	111.65
Purchase	100	111.59
Purchase	750	111.94
Sale	3	111.94
Purchase	2,849	111.89
Purchase	2,148	111.78
Sale	1,261	111.78
Purchase	1,697	111.97

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Call Option	Selling	4,200	112.00	American	5/5/2023
Call Option	Selling	4,200	113.00	American	5/5/2023
Put Option	Selling	3,400	112.00	American	5/5/2023
Put Option	Selling	3,400	113.00	American	5/5/2023

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	2^nd May 2023
Contact name	Sirina Kumar
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	262,400	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	55,400	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	221,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	254,200	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	100,000	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	46,600	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	155,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	200,000	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	95.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	300	110.00	American	7/21/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1089400

Time of Receipt (offset from UTC): 20230502T141134+0100